Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. A Phase II Trial.

NCT07574047 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT07574047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07574047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. A Phase II Trial.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
October 12, 2026
Completion date
June 30, 2032
Enrollment
108 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, melanoma